Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique
Received 18 October 2012
Accepted for publication 22 December 2012
Published 27 May 2013 Volume 2013:8(1) Pages 2065—2076
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Blanca Tobar-Grande,1 Ricardo Godoy,1 Paulina Bustos,2 Carlos von Plessing,1 Elias Fattal,3,4 Nicolas Tsapis,3,4 Claudia Olave,1 Carolina Gómez-Gaete1
1Departamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; 2Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; 3Univ Paris-Sud, Institut Galien Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France; 4CNRS, UMR 8612, Faculté de Pharmacie, Châtenay-Malabry, France
Abstract: In this work, microparticles were prepared by spray-drying using albumin, chondroitin sulfate, and hyaluronic acid as excipients to create a controlled-release methylprednisolone system for use in inflammatory disorders such as arthritis. Scanning electron microscopy demonstrated that these microparticles were almost spherical, with development of surface wrinkling as the methylprednisolone load in the formulation was increased. The methylprednisolone load also had a direct influence on the mean diameter and zeta potential of the microparticles. Interactions between formulation excipients and the active drug were evaluated by x-ray diffraction, differential scanning calorimetry, and thermal gravimetric analysis, showing limited amounts of methylprednisolone in a crystalline state in the loaded microparticles. The encapsulation efficiency of methylprednisolone was approximately 89% in all formulations. The rate of methylprednisolone release from the microparticles depended on the initial drug load in the formulation. In vitro cytotoxic evaluation using THP-1 cells showed that none of the formulations prepared triggered an inflammatory response on release of interleukin-1ß, nor did they affect cellular viability, except for the 9.1% methylprednisolone formulation, which was the maximum test concentration used. The microparticles developed in this study have characteristics amenable to a therapeutic role in inflammatory pathology, such as arthritis.
Keywords: spray-drying, microparticles, methylprednisolone, chondroitin sulfate, hyaluronic acid, cytotoxic assays
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.